Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s innovative TIL ...

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the ...

Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial We analyzed ...

In a new study, TILs significantly predicted both distant disease-free survival and overall survival in early ERBB2-positive breast cancer. TIL levels ≥20% were associated with better outcomes when ...

Richmond, Va.-based VCU Health’s Massey Comprehensive Cancer Center has become the first facility in Virginia to offer tumor-infiltrating lymphocyte therapy for advanced stage melanoma patients. TIL ...

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to ...